

Biography
Professional Summary
Education & Certifications
- Board Certification: American Board of Internal Medicine, Internal Medicine (2022)
- Residency: UCSF Department of Medicine (1994) CA
- Fellowship: Stanford University Medical Center (1997) CA
- Medical Education: Stanford University School of Medicine (1992) CA
Awards & Memberships
- Career Award in the Biomedical Sciences, Burroughs Wellcome Fund (1996-2000)
- Excellence in Research in the Field of Hematopoiesis, Cheryl Whitlock Award (1996)
- Junior Faculty Scholars Award, Howard Hughes Medical Institute (1996-2000)
- Postdoctoral Fellowship, Juvenile Diabetes Foundation (1986-1988)
- Postdoctoral Fellowship, Juvenile Diabetes Foundation (1989-1991)
- Postdoctoral Fellowship, Juvenile Diabetes Foundation (1991-1993)
- Scholar Award, Amy Strelzer Manasevit (2001)
Administrative Appointments
- Member, Stanford Diabetes Research Center (2018 - Present)
Publications
-
Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation.
Dickson, T. M., Kusnierz-Glaz, C. R., Blume, K. G., Negrin, R. S., Hu, W. W., Shizuru, J. A., … Stockerl-Goldstein, K. E. (1999). Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biology of Blood and Marrow Transplantation , 5(5), 299–305. -
Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.
Ito, M., & Shizuru, J. A. (1999). Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model. Biology of Blood and Marrow Transplantation , 5(6), 357–368. -
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy
Hu, W. W., Negrin, R. S., Stockerl-Goldstein, K., JOHNSTON, L. J., Shizuru, J. A., Wong, R. M., … Blume, K. G. (2000). Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: No improvement in outcomes compared with single-course high-dose therapy. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(1), 58–69. -
Effect of oral glutamine supplementation during bone marrow transplantation
Dickson, T. M. C., Wong, R. M., Negrin, R. S., Shizuru, J. A., JOHNSTON, L. J., Hu, W. W., … Stockerl-Goldstein, K. E. (2000). Effect of oral glutamine supplementation during bone marrow transplantation. JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 24(2), 61–66. -
Transplantation of highly purified CD34(+)Thy-I+ hematopoietic stem cells in patients with metastatic breast cancer
Negrin, R. S., Atkinson, K., Leemhuis, T., Hanania, E., Juttner, C., Tierney, K., … Klein, J. (2000). Transplantation of highly purified CD34(+)Thy-I+ hematopoietic stem cells in patients with metastatic breast cancer. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(3), 262–71. -
Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation
Cao, T. M., Negrin, R. S., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Shizuru, J. A., Taylor, T. L., … Hu, W. W. (2000). Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 6(4), 387–94. -
Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection
Shizuru, J. A., Weissman, I. L., Kernoff, R., Masek, M., & Scheffold, Y. C. (2000). Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 97(17), 9555–9560. -
Lymphoid development from stem cells and the common lymphocyte progenitors
Akashi, K., Kondo, M., Cheshier, S., Shizuru, J., Gandy, K., Domen, J., … Weissman, I. L. (1999). Lymphoid development from stem cells and the common lymphocyte progenitors. Presented at the 64th Symposia: Signaling and Gene Expression in the Immune System, NEW YORK,NY: COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT. -
Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production
Baker, J., Verneris, M. R., Ito, M., Shizuru, J. A., & Negrin, R. S. (2001). Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. BLOOD, 97(10), 2923–31. -
High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience
Cao, T. M., Horning, S. F., Negrin, R. S., Hu, W. W., Johnston, L. F., Taylor, T. L., … Stockerl-Goldstein, K. (2001). High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(5), 294–301. -
Immunity to infections following hematopoietic cell transplantation
Brown, J. M., Weissman, I. L., & Shizuru, J. A. (2001). Immunity to infections following hematopoietic cell transplantation. CURRENT OPINION IN IMMUNOLOGY, 13(4), 451–457. -
Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8(+) NK-T cells in the treatment of lymphoma
Verneris, M. R., Ito, M., Baker, E., Arshi, A., Negrin, R. S., & Shizuru, J. A. (2001). Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8(+) NK-T cells in the treatment of lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(10), 532–42. -
Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease
Stuart, M. J., Chao, N. S., Horning, S. J., Wong, R. M., Negrin, R. S., JOHNSTON, L. J., … Goldstein, S. (2001). Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(10), 552–60. -
Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients
Auffermann-Gretzinger, S., Lossos, I. S., Vayntrub, T. A., Leong, W., GRUMET, F. C., Blume, K. G., … Shizuru, J. A. (2002). Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. BLOOD, 99(4), 1442–48. -
Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation
Millan, T. L. T., Shizuru, J. A., Hoffmann, P., Dejbakhsh-Jones, S., Scandling, J. D., GRUMET, F. C., … Strober, S. (2002). Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. TRANSPLANTATION, 73(9), 1386–91. -
Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion
Higuchi, M., Zeng, D. F., Shizuru, J., Gworek, J., Dejbakhsh-Jones, S., Taniguchi, M., & Strober, S. (2002). Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion. JOURNAL OF IMMUNOLOGY, 169(10), 5564–70. -
Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice
Beilhack, G. F., Scheffold, Y. C., Weissman, I. L., TAYLOR, C., Jerabek, L., Burge, M. J., … Shizuru, J. A. (2003). Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. DIABETES, 52(1), 59–68. -
Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation
Shilling, H. G., McQueen, K. L., Cheng, N. W., Shizuru, J. A., Negrin, R. S., & Parham, P. (2003). Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. BLOOD, 101(9), 3730–40. -
Biology of hematopoietic stem cells and progenitors: Implications for clinical application
Kondo, M., Wagers, A. J., Manz, M. G., Prohaska, S. S., Scherer, D. C., Beilhack, G. E., … Weissman, I. L. (2003). Biology of hematopoietic stem cells and progenitors: Implications for clinical application. ANNUAL REVIEW OF IMMUNOLOGY, 21, 759–806. -
Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation
Arber, C., Bitmansour, A., Sparer, T. E., Higgins, J. P., Mocarski, E. S., Weissman, I. L., … Brown, J. M. Y. (2003). Common lymphoid progenitors rapidly engraft and protect against lethal murine cytomegalovirus infection after hematopoietic stem cell transplantation. BLOOD, 102(2), 421–28. -
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma
Horwitz, S. M., Negrin, R. S., Blume, K. G., Breslin, S., Stuart, M. J., Stockerl-Goldstein, K. E., … Horning, S. J. (2004). Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. BLOOD, 103(3), 777–83. -
ANTI-CD4 MONOCLONAL-ANTIBODIES IN THERAPY - CREATION OF NONCLASSICAL TOLERANCE IN THE ADULT
Shizuru, J. A., Alters, S. E., & Fathman, C. G. (1992). ANTI-CD4 MONOCLONAL-ANTIBODIES IN THERAPY - CREATION OF NONCLASSICAL TOLERANCE IN THE ADULT. IMMUNOLOGICAL REVIEWS, 129, 105–30. -
Variable hematopoietic graft rejection and graft-versus-host disease in MHC-matched strains of mice
Cao, T. M., Lo, B., Ranheim, E. A., GRUMET, F. C., & Shizuru, J. A. (2003). Variable hematopoietic graft rejection and graft-versus-host disease in MHC-matched strains of mice. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 100(20), 11571–76. -
Approaches to transplantation tolerance in humans
Strober, S., Lowsky, R. J., Shizuru, J. A., Scandling, J. D., & Millan, M. T. (2004). Approaches to transplantation tolerance in humans. TRANSPLANTATION, 77(6), 932–36. -
Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose
Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., … Lowsky, R. (2005). Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose. BLOOD, 105(6), 2300–2306. -
Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells
Scheffold, C., Scheffold, J. C., Cao, T. M., Gworek, J., & Shizuru, J. A. (2005). Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(1), 1–12. -
Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
Johnston, L. J., Brown, J., Shizuru, J. A., Stockerl-Goldstein, K. E., Stuart, M. J., Blume, K. G., … Chao, N. J. (2005). Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(1), 47–55. -
Hematopoietic stem and progenitor cells: Clinical and preclinical regeneration of the hematolymphoid system
Shizuru, J. A., Negrin, R. S., & Weissman, I. L. (2005). Hematopoietic stem and progenitor cells: Clinical and preclinical regeneration of the hematolymphoid system. ANNUAL REVIEW OF MEDICINE, 56, 509–38. -
CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies
Cao, T. M., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., … Lowsky, R. (2005). CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. EXPERIMENTAL HEMATOLOGY, 33(3), 279–85. -
Prevention of type 1 diabetes with major histocompatibility complex-compatible and nonmarrow ablative hematopoietic stem cell transplants
Beilhack, G. F., Landa, R. R., Masek, M. A., & Shizuru, J. A. (2005). Prevention of type 1 diabetes with major histocompatibility complex-compatible and nonmarrow ablative hematopoietic stem cell transplants. DIABETES, 54(6), 1770–79. -
Protective conditioning for acute graft-versus-host disease
Lowsky, R., Takahashi, T., Liu, Y. P., Dejbakhsh-Jones, S., GRUMET, F. C., Shizuru, J. A., … Strober, S. (2005). Protective conditioning for acute graft-versus-host disease. NEW ENGLAND JOURNAL OF MEDICINE, 353(13), 1321–31. -
Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
Hegenbart, U., Niederwieser, D., Sandmaier, B. M., Maris, M. B., Shizuru, J. A., Greinix, H., … STORB, R. (2006). Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. JOURNAL OF CLINICAL ONCOLOGY, 24(3), 444–453. -
High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., … Stockerl-Goldstein, K. E. (2006). High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(7), 703–11. -
Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes
Chaparro, R. J., Konigshofer, Y., Beilhack, G. F., Shizuru, J. A., McDevitt, H. O., & Chien, Y.-H. (2006). Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 103(33), 12475–80. -
Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation
Baron, F., Storb, R., Storer, B. E., Maris, M. B., Niederwieser, D., Shizuru, J. A., … Sandmaier, B. M. (2006). Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. JOURNAL OF CLINICAL ONCOLOGY, 24(25), 4150–4157. -
Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma
Rezvani, A. R., Storer, B., Maris, M., Sorror, M. L., Agura, E., Maziarz, R. T., … Maloney, D. G. (2008). Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 26(2), 211–17. -
Tolerance and chimerism after renal and hematopoietic-cell transplantation.
Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Millan, M. T., Shizuru, J. A., … Strober, S. (2008). Tolerance and chimerism after renal and hematopoietic-cell transplantation. New England Journal of Medicine, 358(4), 362–68. -
Hepatic parenchymal replacement in mice by transplanted allogeneic hepatocytes is facilitated by bone marrow transplantation and mediated by CD4 cells
Streetz, K. L., Doyonnas, R., Grimm, D., Jenkins, D. D., Fuess, S., Perryman, S., … Kay, M. A. (2008). Hepatic parenchymal replacement in mice by transplanted allogeneic hepatocytes is facilitated by bone marrow transplantation and mediated by CD4 cells. HEPATOLOGY, 47(2), 706–18. -
GENETIC-ANALYSIS OF DIABETES IN THE NONOBESE DIABETIC MOUSE .1. MHC AND T-CELL RECEPTOR BETA-GENE EXPRESSION
Livingstone, A., Edwards, C. T., Shizuru, J. A., & Fathman, C. G. (1991). GENETIC-ANALYSIS OF DIABETES IN THE NONOBESE DIABETIC MOUSE .1. MHC AND T-CELL RECEPTOR BETA-GENE EXPRESSION. JOURNAL OF IMMUNOLOGY, 146(2), 529–34. -
GENETIC DISSECTION OF T-CELL RECEPTOR-V-BETA GENE REQUIREMENTS FOR SPONTANEOUS MURINE DIABETES
Shizuru, J. A., TAYLOREDWARDS, C., Livingstone, A., & Fathman, C. G. (1991). GENETIC DISSECTION OF T-CELL RECEPTOR-V-BETA GENE REQUIREMENTS FOR SPONTANEOUS MURINE DIABETES. JOURNAL OF EXPERIMENTAL MEDICINE, 174(3), 633–38. -
ANTI-CD8 ABROGATES EFFECT OF ANTI-CD4-MEDIATED ISLET ALLOGRAFT SURVIVAL IN RAT MODEL
SEYDEL, K., Shizuru, J., Grossman, D., Wu, A., Alters, S., & Fathman, C. G. (1991). ANTI-CD8 ABROGATES EFFECT OF ANTI-CD4-MEDIATED ISLET ALLOGRAFT SURVIVAL IN RAT MODEL. DIABETES, 40(11), 1430–34. -
TRANSGENIC MICE FOR THE STUDY OF DIABETES-MELLITUS
Shizuru, J. A., & Sarvetnick, N. (1991). TRANSGENIC MICE FOR THE STUDY OF DIABETES-MELLITUS. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2(3), 97–104. -
Complementing mutations in core binding factor leukemias: from mouse models to clinical applications
Mueller, A., Duque, J., Shizuru, J. A., & Luebbert, M. (2008). Complementing mutations in core binding factor leukemias: from mouse models to clinical applications. ONCOGENE, 27(44), 5759–5773. -
Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning
Sorror, M. L., Storer, B. E., Sandmaier, B. M., Maris, M., Shizuru, J., Maziarz, R., … Maloney, D. G. (2008). Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. JOURNAL OF CLINICAL ONCOLOGY, 26(30), 4912–4920. -
The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases
Weissman, I. L., & Shizuru, J. A. (2008). The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. BLOOD, 112(9), 3543–3553. -
Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow
Tsao, G. J., Allen, J. A., Logronio, K. A., Lazzeroni, L. C., & Shizuru, J. A. (2009). Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(9), 3288–93. -
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., … Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099–1109. -
Identification of a Major Susceptibility Locus for Lethal Graft-versus-Host Disease in MHC-Matched Mice
Cao, T. M., Lazzeroni, L. C., Tsai, S., Pang, W. W., Kao, A., Camp, N. J., … Shizuru, J. A. (2009). Identification of a Major Susceptibility Locus for Lethal Graft-versus-Host Disease in MHC-Matched Mice. JOURNAL OF IMMUNOLOGY, 183(1), 462–69. -
Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure
Benjamin, J. E., Chen, G. L., Cao, T. M., Cao, P. D., Wong, R. M., Sheehan, K., … Laport, G. G. (2010). Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. BONE MARROW TRANSPLANTATION, 45(2), 303–9. -
INDUCTION OF DONOR-SPECIFIC UNRESPONSIVENESS TO CARDIAC ALLOGRAFTS IN RATS BY PRETRANSPLANT ANTI-CD4 MONOCLONAL-ANTIBODY THERAPY
Shizuru, J. A., Seydel, K. B., Flavin, T. F., Wu, A. P., Kong, C. C., Hoyt, E. G., … Fathman, C. G. (1990). INDUCTION OF DONOR-SPECIFIC UNRESPONSIVENESS TO CARDIAC ALLOGRAFTS IN RATS BY PRETRANSPLANT ANTI-CD4 MONOCLONAL-ANTIBODY THERAPY. TRANSPLANTATION, 50(3), 366–73. -
Ineffective Vaccination against Solid Tumors Can Be Enhanced by Hematopoietic Cell Transplantation
Filatenkov, A., Mueller, A. M. S., Tseng, W. W.-L., Dejbakhsh-Jones, S., Winer, D., Luong, R., … Strober, S. (2009). Ineffective Vaccination against Solid Tumors Can Be Enhanced by Hematopoietic Cell Transplantation. JOURNAL OF IMMUNOLOGY, 183(11), 7196–7203. -
The biology of allogeneic hematopoietic cell resistance.
Shizuru, J. A., Bhattacharya, D., & Cavazzana-Calvo, M. (2010). The biology of allogeneic hematopoietic cell resistance. Biology of Blood and Marrow Transplantation , 16(1), S2–7. -
Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., … Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145–54. -
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia
Gyurkocza, B., Storb, R., Storer, B. E., Chauncey, T. R., Lange, T., Shizuru, J. A., … Sandmaier, B. M. (2010). Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia. JOURNAL OF CLINICAL ONCOLOGY, 28(17), 2859–2867. -
Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., Lowsky, R., … Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192–99. -
Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation.
Müller, A. M. S., Linderman, J. A., Florek, M., Miklos, D., & Shizuru, J. A. (2010). Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Proceedings of the National Academy of Sciences of the United States of America, 107(33), 14721–26. -
Rapid Reconstitution of Antibody Responses Following Transplantation of Purified Allogeneic Hematopoietic Stem Cells
Linderman, J. A., & Shizuru, J. A. (2011). Rapid Reconstitution of Antibody Responses Following Transplantation of Purified Allogeneic Hematopoietic Stem Cells. JOURNAL OF IMMUNOLOGY, 186(7), 4191–99. -
Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., Brown, J., … Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581–88. -
Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma
Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., Lowsky, R., … Stockerl-Goldstein, K. (2012). Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. BONE MARROW TRANSPLANTATION, 47(4), 516–21. -
Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., … Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679–87. -
Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells
Mueller, A. M. S., Kohrt, H. E. K., Cha, S., Laport, G., Klein, J., Guardino, A. E., … Shizuru, J. A. (2012). Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(1), 125–33. -
A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies
Chen, G. L., Arai, S., Flowers, M. E. D., Otani, J. M., Qiu, J., Cheng, E. C., … Miklos, D. B. (2011). A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. BLOOD, 118(15), 4070–78. -
Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants
Scandling, J. D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Sarwal, M., Millan, M. T., … Strober, S. (2012). Tolerance and Withdrawal of Immunosuppressive Drugs in Patients Given Kidney and Hematopoietic Cell Transplants. AMERICAN JOURNAL OF TRANSPLANTATION, 12(5), 1133–45. -
Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity
Mueller, A. M. S., Shashidhar, S., Kuepper, N. J., Kohrt, H. E. K., Florek, M., Negrin, R. S., … Shizuru, J. A. (2012). Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 109(15), 5820–25. -
Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., … Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145–54. -
The road to purified hematopoietic stem cell transplants is paved with antibodies.
Logan, A. C., Weissman, I. L., & Shizuru, J. A. (2012). The road to purified hematopoietic stem cell transplants is paved with antibodies. Current Opinion in Immunology, 24(5), 640–48. -
Host-derived CD4+T cells attenuate stem cellmediated transfer of autoimmune arthritis in lethally irradiated C57BL/6.g7 mice
Rajasekaran, N., Wang, N., Phi Truong, P., Rinderknecht, C., Macaubas, C., Beilhack, G. F., … Mellins, E. D. (2013). Host-derived CD4+T cells attenuate stem cellmediated transfer of autoimmune arthritis in lethally irradiated C57BL/6.g7 mice. ARTHRITIS AND RHEUMATISM, 65(3), 681–92. -
CARDIAC ALLOGRAFT PROLONGATION IN MICE TREATED WITH COMBINED POSTTRANSPLANTATION TOTAL-LYMPHOID IRRADIATION AND ANTI-L3T4 ANTIBODY THERAPY
TRAGER, D. K., Banks, B. A., Rosenbaum, G. E., HOLM, B. I., Shizuru, J. A., Strober, S., & Fathman, C. G. (1989). CARDIAC ALLOGRAFT PROLONGATION IN MICE TREATED WITH COMBINED POSTTRANSPLANTATION TOTAL-LYMPHOID IRRADIATION AND ANTI-L3T4 ANTIBODY THERAPY. TRANSPLANTATION, 47(4), 587–91. -
IMMUNOTHERAPY OF THE NONOBESE DIABETIC MOUSE - TREATMENT WITH AN ANTIBODY TO T-HELPER LYMPHOCYTES
Shizuru, J. A., TAYLOREDWARDS, C., Banks, B. A., Gregory, A. K., & Fathman, C. G. (1988). IMMUNOTHERAPY OF THE NONOBESE DIABETIC MOUSE - TREATMENT WITH AN ANTIBODY TO T-HELPER LYMPHOCYTES. SCIENCE, 240(4852), 659–62. -
USE OF ANTI-L3T4 AND ANTI-IA TREATMENTS FOR PROLONGATION OF XENOGENEIC ISLET TRANSPLANTS
Kaufman, D. S., Kong, C. S., Shizuru, J. A., Gregory, A. K., & Fathman, C. G. (1988). USE OF ANTI-L3T4 AND ANTI-IA TREATMENTS FOR PROLONGATION OF XENOGENEIC ISLET TRANSPLANTS. TRANSPLANTATION, 46(2), 210–15. -
VASCULAR ADDRESSINS ARE INDUCED ON ISLET VESSELS DURING INSULITIS IN NONOBESE DIABETIC MICE AND ARE INVOLVED IN LYMPHOID-CELL BINDING TO ISLET ENDOTHELIUM
Hanninen, A., TAYLOR, C., STREETER, P. R., Stark, L. S., SARTE, J. M., Shizuru, J. A., … Michie, S. A. (1993). VASCULAR ADDRESSINS ARE INDUCED ON ISLET VESSELS DURING INSULITIS IN NONOBESE DIABETIC MICE AND ARE INVOLVED IN LYMPHOID-CELL BINDING TO ISLET ENDOTHELIUM. JOURNAL OF CLINICAL INVESTIGATION, 92(5), 2509–2515. -
Anti-CD4 antibodies in diabetes.
Shizuru, J. A., & Fathman, C. G. (1993). Anti-CD4 antibodies in diabetes. Immunology Series, 59, 237–52. -
THE USE OF GRANZYME A AS A MARKER OF HEART-TRANSPLANT REJECTION IN CYCLOSPORINE OR ANTI-CD4 MONOCLONAL ANTIBODY-TREATED RATS
CHEN, R. H., IVENS, K. W., Alpert, S., Billingham, M. E., Fathman, C. G., Flavin, T. F., … Griffiths, G. M. (1993). THE USE OF GRANZYME A AS A MARKER OF HEART-TRANSPLANT REJECTION IN CYCLOSPORINE OR ANTI-CD4 MONOCLONAL ANTIBODY-TREATED RATS. TRANSPLANTATION, 55(1), 146–53. -
Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment.
Shizuru, J. A., Jerabek, L., Edwards, C. T., & Weissman, I. L. (1996). Transplantation of purified hematopoietic stem cells: requirements for overcoming the barriers of allogeneic engraftment. Biology of Blood and Marrow Transplantation , 2(1), 3–14. -
From stem cells to lymphocytes: Biology and transplantation
Aguila, H. L., Akashi, K., Domen, J., Gandy, K. L., Lagasse, E., Mebius, R. E., … Weissman, I. L. (1997). From stem cells to lymphocytes: Biology and transplantation. IMMUNOLOGICAL REVIEWS, 157, 13–40. -
Kinetics of mixed chimerism in peripheral blood hematopoietic subpopulations from 120 patients after nonmyeloablative hematopoietic stem cell transplant.
Little, M. T., Baker, J. E., Sandmaier, B. M., Maris, M. B., Maloney, D., Gooley, T., … STORB, R. (2002). Kinetics of mixed chimerism in peripheral blood hematopoietic subpopulations from 120 patients after nonmyeloablative hematopoietic stem cell transplant. BLOOD, 100(11), 39A–39A. -
ISLET ALLOGRAFT SURVIVAL AFTER A SINGLE COURSE OF TREATMENT OF RECIPIENT WITH ANTIBODY TO L3T4
Shizuru, J. A., Gregory, A. K., CHAO, C. T. B., & Fathman, C. G. (1987). ISLET ALLOGRAFT SURVIVAL AFTER A SINGLE COURSE OF TREATMENT OF RECIPIENT WITH ANTIBODY TO L3T4. SCIENCE, 237(4812), 278–280. -
A chromosome 16 quantitative trait locus regulates allogeneic bone marrow engraftment in nonmyeloablated mice
Cao, T. M., Thomas, A., Wang, Y., Tsai, S., Logronio, K., & Shizuru, J. A. (2009). A chromosome 16 quantitative trait locus regulates allogeneic bone marrow engraftment in nonmyeloablated mice. BLOOD, 114(1), 202–10. -
THE MOLECULAR-BASIS OF ANTIGEN-SPECIFIC RECOGNITION BY LYMPHOCYTES-T
Danska, J. S., Livingstone, A. M., Shizuru, J., & Fathman, C. G. (1990). THE MOLECULAR-BASIS OF ANTIGEN-SPECIFIC RECOGNITION BY LYMPHOCYTES-T. Presented at the COLLOQUIUM ON DEFENSE MOLECULES, LAKE TAHOE,CA: WILEY-LISS, INC. -
Of mice and men
Shizuru, J. A. (2006). Of mice and men. BLOOD, 107(7), 2589–2590. -
A non-myeloablative conditioning regimen followed by progenitor cell (CD34+) infusion after kidney transplantation can achieve mixed chimerism and immunosuppressive drug withdrawal
Millan, M. T., Shizuru, J. A., Hoffmann, P., Dejbakhsh-Jones, S., Scandling, J. D., GRUMET, F. C., … Strober, S. (2002). A non-myeloablative conditioning regimen followed by progenitor cell (CD34+) infusion after kidney transplantation can achieve mixed chimerism and immunosuppressive drug withdrawal. FASEB JOURNAL, 16(5), A1030–A1030. -
Toward regenerative medicine
Lagasse, E., Shizuru, J. A., Uchida, N., Tsukamoto, A., & Weissman, I. L. (2001). Toward regenerative medicine. IMMUNITY, 14(4), 425–436. -
Immune reconstitution
Weissman, I. L., & Shizuru, J. A. (1999). Immune reconstitution. NEW ENGLAND JOURNAL OF MEDICINE, 341(16), 1227–1229. -
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
Rotta, M., Storer, B. E., Sahebi, F., Shizuru, J. A., Bruno, B., Lange, T., … Maloney, D. G. (2009). Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. BLOOD, 113(14), 3383–3391. -
Non-myeloablative hematopoietic stem cell transplantation
Maris, M., Sandmaier, B. M., Maloney, D. G., McSweeney, P. A., Woolfrey, A., Chauncey, T., … Storb, R. (2001). Non-myeloablative hematopoietic stem cell transplantation. TRANSFUSION CLINIQUE ET BIOLOGIQUE, 8(3), 231–234. -
Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas
Shustov, A. R., Gooley, T. A., Sandmaier, B. M., Shizuru, J., Sorror, M. L., Sahebi, F., … Maloney, D. G. (2010). Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. BRITISH JOURNAL OF HAEMATOLOGY, 150(2), 170–178. -
Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts
Gyurkocza, B., Cao, T. M., Storb, R. F., Lange, T., Leisenring, W., Franke, G. N., … Sandmaier, B. M. (2009). Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15(10), 1314–22. -
Allogeneic hematopoietic stem cell transplantation: From the nuclear age into the twenty-first century
Storb, R., McSweeney, P. A., Sandmaier, B. M., Nash, R. A., Georges, G., Maloney, D. G., … Niederwieser, D. (2000). Allogeneic hematopoietic stem cell transplantation: From the nuclear age into the twenty-first century. TRANSPLANTATION PROCEEDINGS, 32(7), 2548–2549. -
Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML
Kerbauy, F. R., STORB, R., Hegenbart, U., Gooley, T., Shizuru, J., Al-Ali, H. K., … Sandmaier, B. M. (2005). Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. LEUKEMIA, 19(6), 990–997. -
Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience
Rezvani, A. R., Norasetthada, L., Gooley, T., Sorror, M., Bouvier, M. E., Sahebi, F., … Maloney, D. G. (2008). Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. BRITISH JOURNAL OF HAEMATOLOGY, 143(3), 395–403. -
STRUCTURE, FUNCTION, AND IMMUNE PROPERTIES OF REASSOCIATED ISLET CELLS
Shizuru, J., Trager, D., & Merrell, R. C. (1985). STRUCTURE, FUNCTION, AND IMMUNE PROPERTIES OF REASSOCIATED ISLET CELLS. DIABETES, 34(9), 898–903. -
INHIBITION OF RAT MIXED LYMPHOCYTE PANCREATIC-ISLET CULTURES WITH ANTI-IA IMMUNOTOXIN
Shizuru, J. A., Ramakrishnan, S., Hunt, T., Merrell, R. C., & Fathman, C. G. (1986). INHIBITION OF RAT MIXED LYMPHOCYTE PANCREATIC-ISLET CULTURES WITH ANTI-IA IMMUNOTOXIN. TRANSPLANTATION, 42(6), 660–666. -
GENETIC-CONTROL OF DIABETES-MELLITUS
Weatherall, D., Sarvetnick, N., & Shizuru, J. A. (1992). GENETIC-CONTROL OF DIABETES-MELLITUS. Presented at the 3RD WORLD CONF ON DIABETES RESEARCH, MONTE CARLO,MONACO: SPRINGER VERLAG. -
Nonmyeloablative hematopoietic stem cell transplantation: Transplantation for the 21(st) century
Maris, M., Woolfrey, A., McSweeney, P. A., Sandmaier, B. M., Nash, R. A., Georges, G., … STORB, R. (2001). Nonmyeloablative hematopoietic stem cell transplantation: Transplantation for the 21(st) century. FRONTIERS IN BIOSCIENCE-LANDMARK, 6, G13–G16. -
Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation
Mielcarek, M., Burroughs, L., Leisenring, W., Diaconescu, R., Martin, P. J., Sandmaier, B. M., … STORB, R. (2005). Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. BRITISH JOURNAL OF HAEMATOLOGY, 129(3), 381–391. -
B6.g7 mice reconstituted with BDC2·5 non-obese diabetic (BDC2·5NOD) stem cells do not develop autoimmune diabetes.
Rajasekaran, N., Wang, N., Hang, Y., Macaubas, C., Rinderknecht, C., Beilhack, G. F., … Mellins, E. D. (2013). B6.g7 mice reconstituted with BDC2·5 non-obese diabetic (BDC2·5NOD) stem cells do not develop autoimmune diabetes. Clinical and Experimental Immunology, 174(1), 27–37. -
Pathways analysis of differential gene expression induced by engrafting doses of total body irradiation for allogeneic bone marrow transplantation in mice
Chen, X., Wang, Y., Li, Q., Tsai, S., Thomas, A., Shizuru, J. A., & Cao, T. M. (2013). Pathways analysis of differential gene expression induced by engrafting doses of total body irradiation for allogeneic bone marrow transplantation in mice. IMMUNOGENETICS, 65(8), 597–607. -
Fine mapping of the Bmgr5 quantitative trait locus for allogeneic bone marrow engraftment in mice
Wang, Y., Chen, X., Tsai, S., Thomas, A., Shizuru, J. A., & Cao, T. M. (2013). Fine mapping of the Bmgr5 quantitative trait locus for allogeneic bone marrow engraftment in mice. IMMUNOGENETICS, 65(8), 585–596. -
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
McSweeney, P. A., Niederwieser, D., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., … Storb, R. F. (2001). Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. BLOOD, 97(11), 3390–3400. -
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report
Schultz, K. R., Miklos, D. B., Fowler, D., Cooke, K., Shizuru, J., Zorn, E., … Pavletic, S. Z. (2006). Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker working group report. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(2), 126–37. -
LOSS OF PANCREATIC-ISLET TOLERANCE INDUCED BY BETA-CELL EXPRESSION OF INTERFERON-GAMMA
Sarvetnick, N., Shizuru, J., Liggitt, D., Martin, L., McIntyre, B., Gregory, A., … Stewart, T. (1990). LOSS OF PANCREATIC-ISLET TOLERANCE INDUCED BY BETA-CELL EXPRESSION OF INTERFERON-GAMMA. NATURE, 346(6287), 844–847. -
INFLAMMATORY DESTRUCTION OF PANCREATIC BETA-CELLS IN GAMMA-INTERFERON TRANSGENIC MICE
Sarvetnick, N., Shizuru, J., Liggitt, D., & Stewart, T. (1989). INFLAMMATORY DESTRUCTION OF PANCREATIC BETA-CELLS IN GAMMA-INTERFERON TRANSGENIC MICE. COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 54, 837–842. -
Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., … Lowsky, R. (2014). Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biology of Blood and Marrow Transplantation , 20(6), 837–43. -
Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment.
Müller, A. M. S., Poyser, J., Küpper, N. J., Burnett, C., Ko, R. M., Kohrt, H. E. K., … Shizuru, J. A. (2014). Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment. Blood, 123(18), 2882–92. -
Nonmyeloablative hematopoietic cell transplantation - Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect
Fenstein, L., SANDMAIER, B., Maloney, D., McSweeney, P. A., Maris, M., Flowers, C., … STORB, R. (2001). Nonmyeloablative hematopoietic cell transplantation - Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Presented at the 3rd International Conference on Hematopoietic Stem Cells: Genetics and Medicine, TUBINGEN,GERMANY: NEW YORK ACAD SCIENCES. -
Non-myeloablative haematopoietic stem cell transplants
STORB, R., McSweeney, P. A., Sandmaier, B. M., Nash, R. A., Georges, G., Maloney, D., … Niederwieser, D. (2000). Non-myeloablative haematopoietic stem cell transplants. Presented at the 4th International Stem Cell Workshop on High-Dose Therapy and Transplantation of Haematopoietic Stem Cells, BAD SAAROW PIESKOW,GERMANY: BLACKWELL WISSENSCHAFTS-VERLAGGMBH. -
Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion.
Filatenkov, A., Baker, J., Müller, A. M., Ahn, G.-O., Kohrt, H., Dutt, S., … Strober, S. (2014). Treatment of 4T1 Metastatic Breast Cancer with Combined Hypofractionated Irradiation and Autologous T-Cell Infusion. Radiation Research, 182(2), 163–69. -
Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: The effect of postgrafting mycophenolate mofetil dosing
Maris, M. B., Sandmaier, B. M., Storer, B. E., Maloney, D. G., Shizuru, J. A., Agura, E., … Storb, R. (2006). Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: The effect of postgrafting mycophenolate mofetil dosing. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(4), 454–465. -
Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma
Georges, G. E., Maris, M. B., Maloney, D. G., Sandmaier, B. M., Sorror, M. L., Shizuru, J. A., … Storb, R. (2007). Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 13(4), 423–432. -
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia
Baron, F., Maris, M. B., Storer, B. E., Sandmaier, B. M., Stuart, M. J., McSweeney, P. A., … Storb, R. (2005). HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(4), 272–279. -
Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases
Georges, G. E., Maris, M., Sandmaier, B. M., Maloney, D. G., Feinstein, L., Niederweiser, D., … STORB, R. (2002). Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. Presented at the 29th World Congress of the International-Society-of-Hematology, SEOUL,SOUTH KOREA: SPRINGER JAPAN KK. -
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MNF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases
Niederwieser, D., Maris, M., Shizuru, J. A., Petersdorf, E., Hegenbart, U., Sandmaier, B. M., … Storb, R. F. (2003). Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MNF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. BLOOD, 101(4), 1620–1629. -
Non-myeloablative transplantation.
Maloney, D. G., Sandmaier, B. M., Mackinnon, S., & Shizuru, J. A. (2002). Non-myeloablative transplantation. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 392–421. -
SELECTIVE T-CELL DEPLETION WITH OX-38 ANTI-CD4 MONOCLONAL-ANTIBODY PREVENTS CARDIAC ALLOGRAFT-REJECTION IN RATS
Flavin, T., Shizuru, J., SEYDEL, K., Wu, A., Fujimoto, N., Hoyt, E. G., … Starnes, V. A. (1990). SELECTIVE T-CELL DEPLETION WITH OX-38 ANTI-CD4 MONOCLONAL-ANTIBODY PREVENTS CARDIAC ALLOGRAFT-REJECTION IN RATS. JOURNAL OF HEART TRANSPLANTATION, 9(5), 482–488. -
European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation
Medeiros, B. C., Tian, L., Robenson, S., Laport, G. G., JOHNSTON, L. J., Shizuru, J. A., … Lowsky, R. (2014). European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. BLOOD CANCER JOURNAL, 4. -
Chimerism, Graft Survival, and Withdrawal of Immunosuppressive Drugs in HLA Matched and Mismatched Patients After Living Donor Kidney and Hematopoietic Cell Transplantation.
Scandling, J. D., Busque, S., Shizuru, J. A., Lowsky, R., Hoppe, R., Dejbakhsh-Jones, S., … Strober, S. (2015). Chimerism, Graft Survival, and Withdrawal of Immunosuppressive Drugs in HLA Matched and Mismatched Patients After Living Donor Kidney and Hematopoietic Cell Transplantation. American Journal of Transplantation , 15(3), 695–704. -
Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.
Filatenkov, A., Baker, J., Mueller, A. M. S., Kenkel, J., Ahn, G.-O., Dutt, S., … Strober, S. (2015). Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clinical Cancer Research , 21(16), 3727–39. -
A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency
Dvorak, C. C., Horn, B. N., Puck, J. M., Czechowicz, A., Shizuru, J. A., Ko, R. M., & Cowan, M. J. (2014). A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency. PEDIATRIC TRANSPLANTATION, 18(6), 602–8. -
Genetic susceptibility loci for lethal graft-versus-host disease in MHC-identical mice: Initial results from a genome-wide scan.
Cao, T. M., Pang, W. W., Grumet, R. C., Lazzeroni, L. C., & Shizuru, J. A. (2004). Genetic susceptibility loci for lethal graft-versus-host disease in MHC-identical mice: Initial results from a genome-wide scan. BLOOD, 104(11), 328B–328B. -
Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning
Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., … Lowsky, R. (2015). Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. BONE MARROW TRANSPLANTATION, 50(10), 1286–92.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) »
- Targeted Therapy of Bronchiolitis Obliterans Syndrome »
- TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD »
- Transplantation for Patients With Chronic Lymphocytic Leukemia »
- Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies »
- Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML »
- Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) »
- High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma »
Practice Locations
Blood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive Palo Alto, CA
Palo Alto, CABlood and Marrow Transplant Program (BMT) - 900 Blake Wilbur Drive
900 Blake Wilbur Drive, 2nd Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information » Getting Here »Important Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(60 reviews)
View More »
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referring Physicians.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

- Send referrals online
- View referral status
- Access medical records